Results 101 to 110 of about 149,982 (260)

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53‐Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology

Advanced Science, EarlyView.
In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu, Jinqiu Liu, Yuxuan Deng, Shuyu Hao, Xiaoli Zhang, Mingxu Yang, Chao Guo, Chao Du, Yingdan Chen, Tai Sun, Nan Ji, Zhengping Zhuang, Jie Feng   +12 more
wiley   +1 more source

Mapping the maturation of TCM as an adjuvant to radiotherapy

CoRR
The integration of complementary medicine into oncology represents a paradigm shift that has seen to increasing adoption of Traditional Chinese Medicine (TCM) as an adjuvant to radiotherapy. About twenty-five years since the formal institutionalization of integrated oncology, it is opportune to synthesize the trajectory of evidence for TCM as an ...
P. Bilha Githinji, Aikaterini Melliou, Xi Yuan, Dayan Zhang, Lian Zhang, Zhenglin Chen, Jiansong Ji, Chengying Lv, Jinhao Xu, Peiwu Qin, Dongmei Yu   +10 more
openaire   +2 more sources

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

Advanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang   +9 more
wiley   +1 more source

Adjuvant Radiotherapy [PDF]

, 2020
openaire   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Adjuvant radiotherapy for rectal cancer

Journal of British Surgery, 1999
Steele, R. J. C., Sebag-Montefiore, D
openaire   +3 more sources

Extent of Lymph Node Dissection for cStage I Siewert Type I/II Cancers Based on Lymph Node Metastasis Risk Stratification

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim The optimal surgical strategy and extent of lymph node (LN) dissection for clinical Stage I (cStage I) adenocarcinoma of the esophagogastric junction (AEG) remain controversial. This study aimed to evaluate surgical outcomes and clarify the prevalence and distribution of LN metastasis according to tumor characteristics in cStage I Siewert ...
Masayoshi Terayama, Akihiko Okamura, Tomoyuki Irino, Naoki Takahashi, Jun Kanamori, Yu Imamura, Masaru Hayami, Motonari Ri, Souya Nunobe, Masayuki Watanabe   +9 more
wiley   +1 more source

Optimal Indication of D3 Lymph Node Dissection for Non‐Metastatic Colon Cancers by Tumor Stages: Evaluation of Therapeutic Value Index for Each Lymph Node Station

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aims To explore the therapeutic impact of D3 lymph node dissection for non‐metastatic colon cancers, evaluating the therapeutic value index for each lymph node station according to surgical stages. Methods Consecutive patients with surgical Stage I–III colon and rectosigmoid cancer who underwent curative resection between January 2003 and ...
Akira Ouchi, Kozo Kataoka, Eiji Shinto, Takashi Akiyoshi, Takefumi Yoshida, Yasuyuki Takamizawa, Yukihide Kanemitsu, Hirotoshi Kobayashi, Hideki Ueno, on behalf of the Lymph Nodes Committee of JSCCR   +9 more
wiley   +1 more source

The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery

Cancer Management and Research, 2019
Gaoyuan Wang, Qiang Wang, Xia Fan, Lijuan Ding,* Lihua Dong* Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lijuan ...
Wang G, Wang Q, Fan X, Ding L, Dong L
doaj  

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source